{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:18:33Z","timestamp":1762100313072},"reference-count":37,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.vaccine.2004.12.015","type":"journal-article","created":{"date-parts":[[2005,1,18]],"date-time":"2005-01-18T12:18:57Z","timestamp":1106050737000},"page":"2977-2986","source":"Crossref","is-referenced-by-count":30,"title":["Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid \u03b2-protein and GM-CSF"],"prefix":"10.1016","volume":"23","author":[{"given":"Hong-Duck","family":"Kim","sequence":"first","affiliation":[]},{"given":"Yunpeng","family":"Cao","sequence":"additional","affiliation":[]},{"given":"Fan-Kun","family":"Kong","sequence":"additional","affiliation":[]},{"given":"Kent R.","family":"Van Kampen","sequence":"additional","affiliation":[]},{"given":"Terry L.","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Zhendong","family":"Ma","sequence":"additional","affiliation":[]},{"given":"De-chu C.","family":"Tang","sequence":"additional","affiliation":[]},{"given":"Ken-Ichiro","family":"Fukuchi","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.12.015_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1471-4159.2001.00592.x","article-title":"Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies","volume":"79","author":"Lambert","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.vaccine.2004.12.015_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2004.12.015_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2004.12.015_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2004.12.015_bib5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2004.12.015_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/415462a","article-title":"Nerve inflammation halts trial for Alzheimer's drug","volume":"415","author":"Check","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2004.12.015_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogonzo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2004.12.015_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1056\/NEJM199601043340110","article-title":"DNA vaccines","volume":"334","author":"McDonnell","year":"1996","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2004.12.015_bib9","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1128\/JVI.75.23.11474-11482.2001","article-title":"Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines","volume":"75","author":"Shi","year":"2001","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2004.12.015_bib10","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1038\/sj.onc.1206459","article-title":"GM-CSF-secreting melanoma vaccines","volume":"22","author":"Dranoff","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.vaccine.2004.12.015_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaci.2003.08.015","article-title":"Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF","volume":"112","author":"Martinez-Moczygemba","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2004.12.015_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0300-9084(94)90182-1","article-title":"Determinants of translational fidelity and efficiency in vertebrate mRNAs","volume":"76","author":"Kozak","year":"1994","journal-title":"Biochimie"},{"key":"10.1016\/j.vaccine.2004.12.015_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0014-5793(97)00313-X","article-title":"\u2018Green mice\u2019 as a source of ubiquitous green cells","volume":"407","author":"Okabe","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2004.12.015_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.vaccine.2004.12.015_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/exnr.1994.1101","article-title":"Overexpression of a C-terminal portion of the \u03b2-amyloid precursor protein in mouse brains by transplantation of transformed neuronal cells","volume":"127","author":"Fukuchi","year":"1994","journal-title":"Exp Neurol"},{"key":"10.1016\/j.vaccine.2004.12.015_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-291X(05)80126-3","article-title":"Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity","volume":"182","author":"Fukuchi","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2004.12.015_bib17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF02631450","article-title":"Activity assays of nine heterogeneous promoters in neural and other cultured cells","volume":"30A","author":"Fukuchi","year":"1994","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.vaccine.2004.12.015_bib18","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0002-9440(10)65682-9","article-title":"Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy","volume":"153","author":"Fukuchi","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2004.12.015_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/hum.1997.8.2-187","article-title":"Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor","volume":"8","author":"Lee","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2004.12.015_bib20","first-page":"219","article-title":"High levels of \u03b2-amyloid protein in peripheral blood do not cause cerebral \u00df-amyloidosis in transgenic mice","volume":"149","author":"Fukuchi","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2004.12.015_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0264-410X(02)00464-4","article-title":"The generation and characterization of potentially therapeutic A\u03b2 antibodies in mice: differences according to strain and immunization protocol","volume":"21","author":"Spooner","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.12.015_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/nar\/24.1.214","article-title":"Codon usage tabulated from the international DNA sequence databases","volume":"24","author":"Nakamura","year":"1996","journal-title":"Nucleic Acids Res."},{"issue":"20","key":"10.1016\/j.vaccine.2004.12.015_bib23","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.93.20.10972","article-title":"Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte\/macrophage colony-stimulating factor primes mice for a protective T-cell response","volume":"93","author":"Kwak","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2004.12.015_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00002371-200105000-00003","article-title":"Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells","volume":"24","author":"Kinoshita","year":"2001","journal-title":"J Immunother"},{"issue":"20","key":"10.1016\/j.vaccine.2004.12.015_bib25","first-page":"5770","article-title":"Vector-based vaccine\/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity","volume":"62","author":"Aarts","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.vaccine.2004.12.015_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1078\/0171-2985-00230","article-title":"Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens","volume":"207","author":"Disis","year":"2003","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.vaccine.2004.12.015_bib27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djh028","article-title":"Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer","volume":"96","author":"Nemunaitis","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2004.12.015_bib28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V95.7.2337","article-title":"Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung","volume":"95","author":"Wang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2004.12.015_bib29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4049\/jimmunol.139.4.1113","article-title":"Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells","volume":"139","author":"Morrissey","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2004.12.015_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1172\/JCI116236","article-title":"Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells\/Langerhans cells in human lung and lung cancers","volume":"91","author":"Tazi","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2004.12.015_bib31","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1172\/JCI4160","article-title":"GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice","volume":"102","author":"Stampfli","year":"1998","journal-title":"J Clin Invest"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2004.12.015_bib32","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0264-410X(02)00754-5","article-title":"Abeta1-15 is less immunogenic than Abeta1-40\/42 for intranasal immunization of wild-type mice but may be effective for \u201cboosting\u201d","volume":"21","author":"Leverone","year":"2003","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2004.12.015_bib33_1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm790","article-title":"Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis","volume":"8","author":"McLaurin","year":"2002","journal-title":"Nat Med"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2004.12.015_bib33_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0264-410X(02)00464-4","article-title":"The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol","volume":"21","author":"Spooner","year":"2002","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2004.12.015_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0304-3940(01)01951-6","article-title":"Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42","volume":"307","author":"Town","year":"2001","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.vaccine.2004.12.015_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0197-4580(02)00127-6","article-title":"Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants","volume":"23","author":"Lemere","year":"2002","journal-title":"Neurobiol Aging"},{"issue":"18","key":"10.1016\/j.vaccine.2004.12.015_bib36","doi-asserted-by":"crossref","first-page":"10273","DOI":"10.1073\/pnas.191118298","article-title":"Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease","volume":"98","author":"Monsonego","year":"2001","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04009752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04009752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T17:00:37Z","timestamp":1682960437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04009752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":37,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0264410X04009752"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.12.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}